Incidence of myocardial infarction, stroke, and death in patients with age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor therapy

American Journal of Ophthalmology

Volumn 159, Issue 3, 2015, Pages 557-564.e1

  Ng, Wei Yan ^a   Tan, Gavin Siew Wei ^a,b,c,d   Ong, Peng Guan ^b   Cheng, Ching Yu ^b,c,d   Cheung, Carol Yim Lui ^b,c,d   Wong, Doric Wen Kuan ^a,c,d   Mathur, Ranjana ^a,c,d   Chow, Khuan Yew ^e   Wong, Tien Yin ^a,b,c,d   Cheung, Gemmy Chui Ming ^a,b,c,d  

^a SINGAPORE NATIONAL EYE CENTRE   (Singapore)

^b SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

^e National Registry of Diseases Office   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; AUTOPSY; CEREBROVASCULAR ACCIDENT; DEATH; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; ICD-9; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGAPORE; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CAUSE OF DEATH; EPIDEMIOLOGY; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; MEDICAL RECORD; PUBLIC HEALTH;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CAUSE OF DEATH; FEMALE; HUMANS; INCIDENCE; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MEDICAL RECORD LINKAGE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATIONAL HEALTH PROGRAMS; RETROSPECTIVE STUDIES; SINGAPORE; STROKE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84922622831     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2014.12.005     Document Type: Article

References (46)

1. T.Y. Wong, G. Liew, and P. Mitchell Clinical update: new treatments for age-related macular degeneration Lancet 370 9583 2007 204 206
2. C.S. Brand Management of retinal vascular diseases: a patient-centric approach Eye (Lond) 26 Suppl 2 2012 S1 16
3. U. Schmidt-Erfurth Clinical safety of ranibizumab in age-related macular degeneration Expert Opin Drug Saf 9 1 2010 149 165
4. L.S. Lim, C.M. Cheung, P. Mitchell, and T.Y. Wong Emerging evidence concerning systemic safety of anti-VEGF agents-should ophthalmologists be concerned? Am J Ophthalmol 152 3 2011 329 331
5. C. Schmucker, Y.K. Loke, and C. Ehlken et al. Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review Br J Ophthalmol 95 3 2011 308 317
6. L.H. Curtis, B.G. Hammill, K.A. Schulman, and S.W. Cousins Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration Arch Ophthalmol 128 10 2010 1273 1279
7. K.G. Falavarjani, and Q.D. Nguyen Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature Eye (Lond) 27 7 2013 787 794
8. K. Csaky, and D.V. Do Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies Am J Ophthalmol 148 5 2009 647 656
9. R.P. Singh, S. Srivastava, J.P. Ehlers, R. Bedi, A.P. Schachat, and P.K. Kaiser A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis Br J Ophthalmol 98 Suppl 1 2014 i22 27
10. M.W. Stewart Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug Br J Ophthalmol 96 9 2012 1157 1158
11. C.H. Meyer, and F.G. Holz Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab Eye (Lond) 25 6 2011 661 672
12. U. Chakravarthy, S.P. Harding, and C.A. Rogers et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial Lancet 382 9900 2013 1258 1267
13. R.L. Avery What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned? Br J Ophthalmol 98 Suppl 1 2014 i7 10
14. C. Schmucker, C. Ehlken, and H.T. Agostini et al. A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard PLoS One 7 8 2012 e42701
15. D. Wong, and A.M. Joussen The safety of using anti-VEGF: is there strength in numbers? Graefes Arch Clin Exp Ophthalmol 249 2 2011 161 162
16. M.I. van der Reis, E.C. La Heij, Y. De Jong-Hesse, P.J. Ringens, F. Hendrikse, and J.S. Schouten A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections Retina 31 8 2011 1449 1469
17. Singapore Myocardial Infarction Registry, National Registry of Diseases Office, Ministry of Health, Singapore. Singapore Myocardial Infarction Registry Report No. 1. Trends In Acute Myocardial Infarction In Singapore 2007-2010. Available at https://www.nrdo.gov.sg/uploadedFiles/NRDO/Publications/AMI-16.pdf. Accessed November 26, 2014.
18. Singapore Myocardial Infarction Registry, National Registry of Diseases Office, Ministry of Health, Singapore. Singapore Myocardial Infarction Registry Report No. 2. Trends In Acute Myocardial Infarction In Singapore 2007-2012. Available at https://www.nrdo.gov.sg/uploadedFiles/NRDO/Publications/AMI%20Publication%202014.pdf. Accessed November 26, 2014.
19. Singapore Stroke Registry, National Registry of Diseases Office, Ministry of Health, Singapore. Singapore Stroke Registry Interim Annual Registry Report Trends In Stroke In Singapore 2009-2013. Available at https://www.nrdo.gov.sg/uploadedFiles/NRDO/Stroke-interim-report2013-web-29Oct-final.pdf. Accessed November 26, 2014.
20. Singapore Stroke Registry, National Registry of Diseases Office, Ministry of Health, Singapore. Singapore Stroke Registry Report No. 3. Trends In Stroke In Singapore 2005-2012. Available at https://www.nrdo.gov.sg/uploadedFiles/NRDO/SinStrokeReg2005-2012-4th-Proof.pdf. Accessed November 26, 2014.
21. C.Y. Cheung, W.T. Tay, and M.K. Ikram et al. Retinal microvascular changes and risk of stroke: the Singapore Malay Eye Study Stroke 44 9 2013 2402 2408
22. C.C. Lim, B.W. Teo, and P.G. Ong et al. Chronic kidney disease, cardiovascular disease and mortality: a prospective cohort study in a multi-ethnic Asian population Eur J Prev Cardiol 2014 10.1177/2047487314536873 http://dx.doi.org/10.1177/2047487314536873.
23. V.N. Slee The International Classification of Diseases: ninth revision (ICD-9) Ann Intern Med 88 3 1978 424 426
24. Singapore Stroke Registry, National Registry of Diseases Office, Ministry of Health, Singapore. Singapore Stroke Registry Report No. 2: Trends In Stroke In Singapore 2007-2011. Available at https://www.nrdo.gov.sg/uploadedFiles/NRDO/StrokeMonograph2011-v7.pdf. Accessed November 26, 2014.
25. P.M. Grambsch, and T.M. Therneau Proportional hazards tests and diagnostics based on weighted residuals Biometrika 81 3 1994 515 526
26. Singapore Department of Statistics. Population Trends 2013. Available at http://www.singstat.gov.sg/publications/publications-and-papers/population-and-population
27. G. Liew, and P. Mitchell Ranibizumab for neovascular age-related macular degeneration N Engl J Med 356 7 2007 747 748 author reply 749-750
28. P.J. Rosenfeld, D.M. Brown, and J.S. Heier et al. Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1419 1431
29. T. Ueta, Y. Yanagi, Y. Tamaki, and T. Yamaguchi Cerebrovascular accidents in ranibizumab Ophthalmology 116 2 2009 362
30. N.M. Bressler, D.S. Boyer, and D.F. Williams et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials Retina 32 9 2012 1821 1828
31. F.G. Holz, F. Bandello, and M. Gillies et al. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme Br J Ophthalmol 97 9 2013 1161 1167
32. American Society of Retina Specialists. Preferences and Trends (PAT) Survey 2014. Available at http://www.asrs.org/content/documents/-2014patsurvey-website-final.pdf. Accessed November 26, 2014.
33. American Society of Retina Specialists. Preferences and Trends (PAT) Survey 2013. Available at http://www.asrs.org/content/documents/-2013patsurveytrendingdata.pdf. Accessed November 26, 2014.
34. American Society of Retina Specialists. Preferences and Trends (PAT) Survey 2012. Available at http://www.asrs.org/content/documents/-2012asrspatsurveyresults.pdf. Accessed November 26, 2014.
35. American Society of Retina Specialists. Preferences and Trends (PAT) Survey 2011. Available at http://www.asrs.org/content/documents/-patsurvey2011.pdf. Accessed November 26, 2014.
36. W.Y. Ng, C.M. Cheung, and R. Mathur et al. Trends in age-related macular degeneration management in Singapore Optom Vis Sci 91 8 2014 872 877
37. R.J. Campbell, S.S. Gill, S.E. Bronskill, J.M. Paterson, M. Whitehead, and C.M. Bell Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study BMJ 345 2012 e4203
38. A. Kemp, D.B. Preen, and N. Morlet et al. Myocardial infarction after intravitreal vascular endothelial growth factor inhibitors: a whole population study Retina 33 5 2013 920 927
39. R.M. Dafer, M. Schneck, T.R. Friberg, and W.M. Jay Intravitreal ranibizumab and bevacizumab: a review of risk Semin Ophthalmol 22 3 2007 201 204
40. M. Tolentino Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease Surv Ophthalmol 56 2 2011 95 113
41. L. Wu, M.A. Martinez-Castellanos, and H. Quiroz-Mercado et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES) Graefes Arch Clin Exp Ophthalmol 246 1 2008 81 87
42. Comparison of Age-related Macular Degeneration Treatments Trials Research Group D.F. Martin, and M.G. Maguire et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 7 2012 1388 1398
43. A.M. Carneiro, D. Barthelmes, and M.S. Falcao et al. Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab Ophthalmologica 225 4 2011 211 221
44. R.J. Campbell, C.M. Bell, and J.M. Paterson et al. Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis Ophthalmology 119 8 2012 1604 1608
45. C.M. Cheung, and T.Y. Wong Treatment of age-related macular degeneration Lancet 382 9900 2013 1230 1232
46. T.Y. Wong, G. Tikellis, C. Sun, R. Klein, D.J. Couper, and A.R. Sharrett Age-related macular degeneration and risk of coronary heart disease: the Atherosclerosis Risk in Communities Study Ophthalmology 114 1 2007 86 91